3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
You turn 65, sign up for Medicare, and a stack of mail arrives pushing standalone Part D drug plans. For years, many retirees picked one and never looked again. For 2026, and for the 2027 plan year that follows, that habit deserves a second look. The Inflation Reduction Act has reshaped Part D costs, the standalone market has contracted, and open enrollment runs through December 7, 2026.
Part D still matters. The late enrollment penalty is permanent, and it applies to anyone who goes without creditable drug coverage for a continuous period after their initial enrollment window. The decision comes down to which drug coverage path fits the prescriptions you take now and the income you reported to the government.
The numbers that frame the decision
- Part D national base beneficiary premium of $38.99 per month in 2026, rising to $41.33 in 2027. Medicare uses this benchmark to calculate late enrollment penalties and IRMAA surcharges. The 2026 figure rose 6% from $36.78 in 2025, which is the maximum increase the law allows. Your plan’s actual premium depends on the carrier and state, so this figure is a formula input rather than the bill most enrollees receive.
- Maximum Part D deductible of $615 in 2026, rising to $700 in 2027. No plan can charge more than the cap before cost-sharing begins, and many plans charge less or nothing at all. Total annual cost, not the monthly premium alone, is the figure to compare.
- Annual out-of-pocket cap on prescriptions of $2,100 in 2026, rising to $2,400 in 2027. Once your covered drug spending reaches the limit, you pay nothing more for covered Part D drugs for the rest of the year. Ten high-cost drugs, including Eliquis, Jardiance, and Xarelto, carry negotiated prices that took effect in 2026.
- IRMAA surcharge range for higher-income retirees of $14.50 to $91.00 per month: For 2026, the surcharge applies when 2024 modified adjusted gross income tops $109,000 for single filers or $218,000 for joint filers. The single-filer threshold rose from $106,000 in 2025. The surcharge is added on top of your plan premium, no matter which Part D plan you pick.
Premium patterns are where plan choice matters most. KFF reports that 79% of Medicare Advantage drug plan enrollees without low-income subsidies paid no monthly Part D premium in 2026, compared with 28% of standalone plan enrollees.
What changed between 2026 and 2027
The first shift is the premium support. CMS announced that its Part D Premium Stabilization Demonstration will end on December 31, 2026, a year earlier than originally scheduled. The $10 monthly subsidy and the $50 cap on annual premium increases both disappear after 2026, so standalone enrollees should expect their premiums to move.
The second shift is drug pricing. CMS estimated that the first round of negotiated prices would reduce enrollee out-of-pocket spending by about $1.5 billion in 2026. A 30-day supply of Januvia now costs $113, a 79% drop from its 2023 list price, and Eliquis costs $231, 56% below its 2023 list price. Fifteen more drugs receive negotiated prices in 2027.
The late enrollment penalty remains the most important reason not to skip Part D entirely. Medicare adds 1% of the base premium for each full month a person goes without creditable coverage, and the add-on never expires. Sixty uncovered months works out to about $23 a month on the 2026 base, and about $25 a month on the 2027 base. For most retirees, a low-cost plan costs less than that penalty over time.
The standalone market has also shrunk. KFF counts 360 stand-alone plans for 2026, a 22% decrease from 2025, and reports that most states offer between 8 and 12 options. For 2027, KFF projects that the number of standalone plans available to the average beneficiary will fall from 11 to 9, the fourth straight year of decline.
Some enrollees will be forced to switch. KFF estimates that about 1.2 million standalone plan enrollees will have their plans terminated at the end of 2026, or 6% of that group, double the share affected last year. KFF also finds that no zero-premium standalone plans will be available to 2027 enrollees who lack low-income subsidies.
Three reasons to reconsider a standalone plan
- The cheapest compliant plan often wins for light users. If you take few or no drugs, Part D’s main job is to avoid the lifetime penalty and keep access to the cap if your health changes. Paying for a richer formulary you never use adds cost with little return. Some retirees pair a low-premium plan with discount pricing from GoodRx (NASDAQ:GDRX | GDRX Price Prediction) or Costco (NASDAQ:COST) for generics, then compare that total against the annual cost of a mid-tier plan.
- A Medicare Advantage drug plan (MA-PD) may already include it. An MA-PD bundles drug coverage into a Medicare Advantage plan, and most Part D enrollees choose that route. KFF reports that 56% of Part D enrollees were in Medicare Advantage drug plans in 2026. The tradeoffs are network rules and prior authorization requirements, which matter most if you see several specialists or travel often. Healthy retirees who want one bill and a lower upfront premium may find that an MA-PD settles the question. Original Medicare plus a standalone plan still offers broader access to any provider.
- IRMAA surcharges can stack on top of a premium. A higher-income retiree pays the Part D surcharge of up to $91 a month on top of the premium for the chosen plan. The surcharge uses your 2024 return, so it reflects income from two years earlier. The thresholds work like a cliff: a single filer whose income passes $109,000 pays a Part B total of $284.10 a month instead of $202.90.
What to do during open enrollment
Start with your current medication list and your income from two years ago. IRMAA for 2026 is based on your 2024 tax return, so those earnings already shape your bill. If you have creditable drug coverage through a former employer or a spouse’s active plan, keep the paperwork. That coverage stops the penalty clock, and losing it later can trigger a special enrollment period.
Avoid autopilot. Plans revise formularies and premiums every year, and the end of the premium subsidy makes 2027 harder to predict. Last year’s plan may no longer be the best fit or even be offered on the same terms. Use Medicare.gov’s plan finder with your current drug list before open enrollment closes on December 7, 2026, and confirm that the cap, the premium, and your prescriptions still line up.
Editor’s note: This update adds CMS’s 2027 Part D figures, including a $41.33 base beneficiary premium, a $2,400 out-of-pocket cap, and a $700 maximum deductible, and notes that the premium stabilization subsidy ends after 2026. It also removes premium averages and Medicare Advantage figures that could not be verified, and adds KFF’s projection that standalone plans available to the average beneficiary will fall from 11 to 9 in 2027.
Contact [email protected] for any questions or corrections.








